Cancer immunotherapy: On the trail of a cure?

Thomas S. Griffith; Troy J. Kemp; Aaron T. Ludwig; Jill M. Moore; Rebecca L. Vanoosten

doi:10.1007/1-4020-3302-8_11

Cancer immunotherapy: On the trail of a cure?

Thomas S. Griffith, Troy J. Kemp, Aaron T. Ludwig, Jill M. Moore, Rebecca L. Vanoosten

Urology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Since its discovery in 1995, numerous studies have investigated the potential of using TRAIL (TNF-related apoptosis-inducing ligand) as an alternative cancer therapeutic, since it is a potent inducer of apoptosis in tumor cells but not in normal cells and tissues. As a consequence, a great deal is known about TRAIL/TRAIL receptor expression, the molecular mechanism of TRAIL receptor signaling, and methods of altering tumor cell sensitivity to TRAIL-induced apoptosis. Translating the preclinical TRAIL studies into the clinic is beginning, with the hope that TRAIL will retain all of its tumoricidal activity against human primary tumors in situ with no toxic side effects.

Original language	English (US)
Title of host publication	Application of Apoptosis to Cancer Treatment
Publisher	Springer Netherlands
Pages	247-270
Number of pages	24
ISBN (Print)	1402033036, 9781402033032
DOIs	https://doi.org/10.1007/1-4020-3302-8_11
State	Published - 2005

Keywords

TRAIL
adenovirus
apoptosis
immunotherapy
tumor

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1007/1-4020-3302-8_11

OpenUrl availability

Full text

Cite this

@inbook{cd49f1e1911c4f8dab8f7ac88eb1ebe8,

title = "Cancer immunotherapy: On the trail of a cure?",

abstract = "Since its discovery in 1995, numerous studies have investigated the potential of using TRAIL (TNF-related apoptosis-inducing ligand) as an alternative cancer therapeutic, since it is a potent inducer of apoptosis in tumor cells but not in normal cells and tissues. As a consequence, a great deal is known about TRAIL/TRAIL receptor expression, the molecular mechanism of TRAIL receptor signaling, and methods of altering tumor cell sensitivity to TRAIL-induced apoptosis. Translating the preclinical TRAIL studies into the clinic is beginning, with the hope that TRAIL will retain all of its tumoricidal activity against human primary tumors in situ with no toxic side effects.",

keywords = "TRAIL, adenovirus, apoptosis, immunotherapy, tumor",

author = "Griffith, {Thomas S.} and Kemp, {Troy J.} and Ludwig, {Aaron T.} and Moore, {Jill M.} and Vanoosten, {Rebecca L.}",

year = "2005",

doi = "10.1007/1-4020-3302-8_11",

language = "English (US)",

isbn = "1402033036",

pages = "247--270",

booktitle = "Application of Apoptosis to Cancer Treatment",

publisher = "Springer Netherlands",

}

TY - CHAP

T1 - Cancer immunotherapy

T2 - On the trail of a cure?

AU - Griffith, Thomas S.

AU - Kemp, Troy J.

AU - Ludwig, Aaron T.

AU - Moore, Jill M.

AU - Vanoosten, Rebecca L.

PY - 2005

Y1 - 2005

N2 - Since its discovery in 1995, numerous studies have investigated the potential of using TRAIL (TNF-related apoptosis-inducing ligand) as an alternative cancer therapeutic, since it is a potent inducer of apoptosis in tumor cells but not in normal cells and tissues. As a consequence, a great deal is known about TRAIL/TRAIL receptor expression, the molecular mechanism of TRAIL receptor signaling, and methods of altering tumor cell sensitivity to TRAIL-induced apoptosis. Translating the preclinical TRAIL studies into the clinic is beginning, with the hope that TRAIL will retain all of its tumoricidal activity against human primary tumors in situ with no toxic side effects.

AB - Since its discovery in 1995, numerous studies have investigated the potential of using TRAIL (TNF-related apoptosis-inducing ligand) as an alternative cancer therapeutic, since it is a potent inducer of apoptosis in tumor cells but not in normal cells and tissues. As a consequence, a great deal is known about TRAIL/TRAIL receptor expression, the molecular mechanism of TRAIL receptor signaling, and methods of altering tumor cell sensitivity to TRAIL-induced apoptosis. Translating the preclinical TRAIL studies into the clinic is beginning, with the hope that TRAIL will retain all of its tumoricidal activity against human primary tumors in situ with no toxic side effects.

KW - TRAIL

KW - adenovirus

KW - apoptosis

KW - immunotherapy

KW - tumor

UR - http://www.scopus.com/inward/record.url?scp=84900655359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900655359&partnerID=8YFLogxK

U2 - 10.1007/1-4020-3302-8_11

DO - 10.1007/1-4020-3302-8_11

M3 - Chapter

AN - SCOPUS:84900655359

SN - 1402033036

SN - 9781402033032

SP - 247

EP - 270

BT - Application of Apoptosis to Cancer Treatment

PB - Springer Netherlands

ER -

Cancer immunotherapy: On the trail of a cure?

Abstract

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this